CA2375972A1 - Pharmaceutical composition containing sibutramine and orlistat - Google Patents
Pharmaceutical composition containing sibutramine and orlistat Download PDFInfo
- Publication number
- CA2375972A1 CA2375972A1 CA002375972A CA2375972A CA2375972A1 CA 2375972 A1 CA2375972 A1 CA 2375972A1 CA 002375972 A CA002375972 A CA 002375972A CA 2375972 A CA2375972 A CA 2375972A CA 2375972 A1 CA2375972 A1 CA 2375972A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- treatment
- obesity
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9914744.9 | 1999-06-24 | ||
GBGB9914744.9A GB9914744D0 (en) | 1999-06-24 | 1999-06-24 | Therapeutic agents |
PCT/EP2000/005542 WO2001000205A1 (en) | 1999-06-24 | 2000-06-16 | Pharmaceutical composition containing sibutramine and orlistat |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2375972A1 true CA2375972A1 (en) | 2001-01-04 |
Family
ID=10855955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002375972A Abandoned CA2375972A1 (en) | 1999-06-24 | 2000-06-16 | Pharmaceutical composition containing sibutramine and orlistat |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1187606A1 (xx) |
JP (1) | JP2003503349A (xx) |
KR (1) | KR20020015357A (xx) |
CN (1) | CN1358092A (xx) |
AU (1) | AU5533200A (xx) |
BG (1) | BG106180A (xx) |
BR (1) | BR0011880A (xx) |
CA (1) | CA2375972A1 (xx) |
CZ (1) | CZ20014613A3 (xx) |
GB (1) | GB9914744D0 (xx) |
HK (1) | HK1049278A1 (xx) |
HU (1) | HUP0201878A3 (xx) |
IL (1) | IL147079A0 (xx) |
MX (1) | MXPA01012936A (xx) |
NO (1) | NO20016224L (xx) |
PL (1) | PL352402A1 (xx) |
RU (1) | RU2229289C2 (xx) |
SK (1) | SK18242001A3 (xx) |
TR (1) | TR200103699T2 (xx) |
WO (1) | WO2001000205A1 (xx) |
ZA (1) | ZA200109989B (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696495B2 (en) * | 1998-12-02 | 2004-02-24 | Snowden Pharmaceuticals, Llc | Treatment of disorders secondary to organic impairments |
US20040214804A1 (en) * | 2003-04-25 | 2004-10-28 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and an anti-obesity agent |
RU2007119315A (ru) | 2004-10-25 | 2008-11-27 | Зольвай Фармасьютиклз Гмбх (De) | Фармацевтические композиции, содержащие антагонисты каннабиноидного рецептора св1 и открыватели калиевых каналов, предназначенные для лечения сахарного диабета типа i, ожирения и связанных с ними состояний |
US8604244B2 (en) | 2010-07-02 | 2013-12-10 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives |
US7989500B2 (en) | 2006-09-15 | 2011-08-02 | Reviva Pharmaceuticals, Inc. | Synthesis, methods of using, and compositions of cycloalkylmethylamines |
EP2083867A1 (en) * | 2006-11-22 | 2009-08-05 | SK Chemicals, Co., Ltd. | Inclusion complex of sibutramine and beta-cyclodextrin |
CN101890017A (zh) * | 2009-05-22 | 2010-11-24 | 北京奥萨医药研究中心有限公司 | 含有西布曲明和他汀类降脂药物的药物组合物及其用途 |
MX336980B (es) * | 2010-12-21 | 2016-02-09 | Senosiain S A De C V Lab | Combinacion y composicion para el tratamiento de obesidad. |
IN2014MN01407A (xx) | 2011-12-30 | 2015-07-03 | Reviva Pharmaceuticals Inc |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9727131D0 (en) * | 1997-12-24 | 1998-02-25 | Knoll Ag | Therapeutic agents |
-
1999
- 1999-06-24 GB GBGB9914744.9A patent/GB9914744D0/en not_active Ceased
-
2000
- 2000-06-16 KR KR1020017016575A patent/KR20020015357A/ko not_active Application Discontinuation
- 2000-06-16 IL IL14707900A patent/IL147079A0/xx unknown
- 2000-06-16 CA CA002375972A patent/CA2375972A1/en not_active Abandoned
- 2000-06-16 AU AU55332/00A patent/AU5533200A/en not_active Abandoned
- 2000-06-16 HU HU0201878A patent/HUP0201878A3/hu unknown
- 2000-06-16 PL PL00352402A patent/PL352402A1/xx not_active Application Discontinuation
- 2000-06-16 SK SK1824-2001A patent/SK18242001A3/sk unknown
- 2000-06-16 EP EP00940379A patent/EP1187606A1/en not_active Withdrawn
- 2000-06-16 RU RU2002102076/14A patent/RU2229289C2/ru not_active IP Right Cessation
- 2000-06-16 CZ CZ20014613A patent/CZ20014613A3/cs unknown
- 2000-06-16 WO PCT/EP2000/005542 patent/WO2001000205A1/en not_active Application Discontinuation
- 2000-06-16 JP JP2001505914A patent/JP2003503349A/ja active Pending
- 2000-06-16 BR BR0011880-0A patent/BR0011880A/pt not_active IP Right Cessation
- 2000-06-16 CN CN00809372A patent/CN1358092A/zh active Pending
- 2000-06-16 TR TR2001/03699T patent/TR200103699T2/xx unknown
- 2000-06-16 MX MXPA01012936A patent/MXPA01012936A/es unknown
-
2001
- 2001-12-04 BG BG106180A patent/BG106180A/xx unknown
- 2001-12-05 ZA ZA200109989A patent/ZA200109989B/xx unknown
- 2001-12-19 NO NO20016224A patent/NO20016224L/no not_active Application Discontinuation
-
2003
- 2003-01-09 HK HK03100246.9A patent/HK1049278A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20014613A3 (cs) | 2003-04-16 |
BG106180A (en) | 2002-08-30 |
JP2003503349A (ja) | 2003-01-28 |
SK18242001A3 (sk) | 2003-02-04 |
ZA200109989B (en) | 2003-02-26 |
EP1187606A1 (en) | 2002-03-20 |
WO2001000205A1 (en) | 2001-01-04 |
KR20020015357A (ko) | 2002-02-27 |
CN1358092A (zh) | 2002-07-10 |
HK1049278A1 (zh) | 2003-05-09 |
HUP0201878A2 (hu) | 2003-08-28 |
IL147079A0 (en) | 2002-08-14 |
RU2229289C2 (ru) | 2004-05-27 |
HUP0201878A3 (en) | 2005-04-28 |
TR200103699T2 (tr) | 2002-04-22 |
GB9914744D0 (en) | 1999-08-25 |
MXPA01012936A (es) | 2004-04-21 |
PL352402A1 (en) | 2003-08-25 |
NO20016224L (no) | 2002-02-12 |
NO20016224D0 (no) | 2001-12-19 |
BR0011880A (pt) | 2002-03-19 |
AU5533200A (en) | 2001-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2367666C (en) | Method of treating eating disorders | |
US6403641B2 (en) | Therapeutic agents | |
US6376552B1 (en) | Treatment of gallstones | |
CA2375972A1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
US6441046B1 (en) | Control of metabolism | |
CA2376213A1 (en) | Therapeutic agents | |
AU773490B2 (en) | Treatment of osteoarthritis | |
US6403650B1 (en) | Treatment of pulmonary hypertension | |
WO2000056308A1 (en) | Prevention of cardiovascular disease | |
MXPA00006201A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
CA2367045A1 (en) | Treatment of certain cancers associated with weight gain | |
CA2368416A1 (en) | Treatment of gallstones | |
CA2367268A1 (en) | Weight loss after pregnancy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |